Risks of recurrent events after acute coronary syndrome, with respect to multimorbidity.

<p>Risks of recurrent events after acute coronary syndrome, with respect to multimorbidity.</p

Clinical management after acute coronary syndrome, by presence of cardiovascular and non-cardiovascular multimorbidity.

<p>Clinical management after acute coronary syndrome, by presence of cardiovascular and non-cardiovascular multimorbidity.</p

Coronary events rates after acute coronary syndrome, by presence of cardiovascular and non-cardiovascular multimorbidity.

<p>Coronary events rates after acute coronary syndrome, by presence of cardiovascular and non-cardiovascular multimorbidity.</p

Characteristics of patients with acute coronary syndrome, by presence of cardiovascular and non-cardiovascular multimorbidity.

<p>Characteristics of patients with acute coronary syndrome, by presence of cardiovascular and non-cardiovascular multimorbidity.</p

Cardiovascular events rates after acute coronary syndrome, by presence of cardiovascular and non-cardiovascular multimorbidity.

<p>Cardiovascular events rates after acute coronary syndrome, by presence of cardiovascular and non-cardiovascular multimorbidity.</p

Association between anticoagulation practices and length of hospital stay^*.

<p>Association between anticoagulation practices and length of hospital stay^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0148348#t004fn002" target="_blank">*</a>}.</p

Patient baseline characteristics (N = 991).

<p>Patient baseline characteristics (N = 991).</p

Associations between anticoagulation practices and clinical outcomes at 6 months.

<p>Associations between anticoagulation practices and clinical outcomes at 6 months.</p

Thrombendarterectomy tissue for secretome production and immunohistochemistry.

<p>a) Tissue sample as it was received from the surgical department. b) The tissue was separated into the plaque part (I) for production of the plaque secretome, and the best preserved part (II) for production of the control secretome.</p

Detection of JUP isoforms in plasma from PAOD patients with atherosclerosis and in plasma from a swine model of myocardial infarction without atherosclerosis and plaque rupture.

<p>a) Western blot containing recombinant GST-tagged JUP (lane 1, 107 kD), ACS plasma (lane 2), control plasma (lane 3) and plasma from four PAOD patients (lanes 4 to 7) were detected with mAb 2G9 (which replaced 2C9). JUP-55 and JUP-30 are clearly detected besides JUP-81. b) Western blot containing recombinant GST-tagged JUP (lane 1, 107 kD), ACS plasma (lane 2), control plasma (lane 3) and plasma samples from swine before ligation (lanes 4 and 7), three hours after ligation (lanes 5 and 8) and three days after ligation (lanes 6 and 9) were detected with mAb 2G9. JUP-81 was not detected in the swine samples, whereas JUP-30 and a protein band with a slightly larger molecular weight were detected with similar intensities before and after ligation.</p